Duration of Febuxostat Therapy After Acute Gout Attack

Introduction to Febuxostat Therapy

The American College of Physicians recommends that febuxostat should be continued indefinitely once initiated for recurrent gout, as urate-lowering therapy is a chronic treatment that maintains serum urate below 6 mg/dL to prevent future attacks 1, 2

The American College of Physicians strongly recommends against initiating long-term urate-lowering therapy in patients with infrequent gout attacks (<2 episodes per year) because the benefits of long-term use have not been demonstrated in this population 1, 2
Febuxostat should be initiated for patients with recurrent gout (≥2 episodes per year), presence of tophi, chronic kidney disease stage ≥3, radiographic damage from gout, serum uric acid >9 mg/dL, or history of urolithiasis 4, 5, 6

When initiating febuxostat, concurrent anti-inflammatory prophylaxis should be provided for more than 8 weeks, preferably 6 months, to prevent acute gout flares 1, 2, 5, 7
Urate-lowering therapy does not reduce gout attacks in the first 6 months and may paradoxically increase flare frequency initially due to mobilization of urate crystals from tissue deposits 1, 2, 5
Discontinuing prophylaxis after only 8 weeks approximately doubles the rate of acute gout flares 5, 8

Low-dose colchicine (0.5-1 mg/day) or low-dose NSAIDs can be used as prophylaxis options 5, 7

Once started, febuxostat is typically continued indefinitely as chronic therapy, with moderate to high-quality evidence demonstrating that urate-lowering therapy reduces gout attacks after 1 year of treatment 1, 2, 5
Long-term treatment (3-5 years) with febuxostat maintained target serum urate levels and resulted in near elimination of gout flares and improved tophus resolution 8

The starting dose of febuxostat is 40 mg once daily, with a target serum urate of <6 mg/dL (357 µmol/L) 3, 4, 5
Dose escalation to febuxostat 80 mg/day may be necessary if the target serum urate level is not achieved 6, 7
Serum urate levels should be monitored regularly to ensure they remain below 6 mg/dL 3, 5

Febuxostat should not be discontinued completely after achieving symptom control, as this leads to recurrence of gout flares 3
Febuxostat should not be started without concurrent anti-inflammatory prophylaxis, as this significantly increases the risk of acute flares 3, 5
Prophylaxis should not be stopped before 8 weeks, as early discontinuation increases breakthrough attacks 5, 8
Adverse effects of febuxostat, such as abdominal pain, diarrhea, musculoskeletal pain, and liver function abnormalities, should be monitored 1, 2, 3, 7